SANOBER KABLE
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
- Where
- DENISON, TX
- NPI
- 1295876399
- Received
- $230,168 in 1,578 records, 2019 to 2025 ($228,768 general, $1,400 research)
- As principal investigator
- $681,216 of research payments to others in 207 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 192 | $29,030 |
| 2024 | General payment | 166 | $52,440 |
| 2023 | General payment | 113 | $38,541 |
| 2022 | General payment | 229 | $26,478 |
| 2021 | General payment | 287 | $32,971 |
| 2020 | General payment | 312 | $27,550 |
| 2019 | General payment | 278 | $21,755 |
| 2019 | Research payment | 1 | $1,400 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 80 | $167,655 |
| Food and Beverage | 1,448 | $27,162 |
| Consulting Fee | 7 | $22,038 |
| Travel and Lodging | 35 | $8,806 |
| Education | 7 | $3,105 |
| Research payment | 1 | $1,400 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-18 | ANI Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-12-18 | GlaxoSmithKline, LLC. | $22 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-18 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-12-16 | Viatris Specialty LLC | $18 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-12-16 | ARS Pharmaceuticals Operations, Inc. | $13 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-12-16 | Insmed, Inc. | $6 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-12-15 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-11 | Viatris Specialty LLC | $20 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-12-11 | United Therapeutics Corporation | $6 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-12-11 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-11 | United Therapeutics Corporation | $2 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-12-09 | Verona Pharma, Inc. | $36 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-12-09 | Intuitive Surgical, Inc. | $24 | Food and Beverage | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2025 | |
| 2025-12-08 | Baxter Healthcare | $20 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-12-04 | Regeneron Healthcare Solutions, Inc. | $31 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-04 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-12-03 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-12-03 | Bayer Healthcare Pharmaceuticals Inc. | $13 | Food and Beverage | In-kind items and services | Adempas Drug, Cardio-pulmonary | 2025 | |
| 2025-12-03 | Insmed, Inc. | $10 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-12-02 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-11-24 | AstraZeneca Pharmaceuticals LP | $30 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-24 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-11-20 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $13 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-19 | Insmed, Inc. | $20 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-11-19 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-11-18 | Grifols USA, LLC | $20 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-11-17 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-11-13 | United Therapeutics Corporation | $20 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-11-10 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | Insmed, Inc. | $15 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-27 | AOP Health US, LLC | $342 | Food and Beverage | In-kind items and services | Rapiblyk Drug, Cardiovascular | 2025 | |
| 2025-10-27 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-10-27 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-23 | GENZYME CORPORATION | $10 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-23 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-10-21 | Takeda Pharmaceuticals U.S.A., Inc. | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-21 | Actelion Pharmaceuticals US, Inc. | $18 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-10-20 | GENZYME CORPORATION | $87 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-16 | United Therapeutics Corporation | $31 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-10-14 | Axsome Therapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-10-14 | Regeneron Healthcare Solutions, Inc. | $13 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-09 | GENZYME CORPORATION | $43 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-09 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-10-08 | Insmed, Inc. | $20 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-02 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-02 | Insmed, Inc. | $9 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-01 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-10-01 | Insmed, Inc. | $8 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-09-30 | JAZZ PHARMACEUTICALS INC. | $29 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-09-30 | Baxter Healthcare | $20 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-09-25 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-09-24 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-24 | Viatris Specialty LLC | $18 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-22 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-17 | GENZYME CORPORATION | $2,108 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-16 | JAZZ PHARMACEUTICALS INC. | $42 | Education | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $135 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $63 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $54 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $40 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $1,224 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $164 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-11 | GENZYME CORPORATION | $19 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-09 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-09-08 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-09-08 | United Therapeutics Corporation | $7 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-09-04 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-09-04 | Insmed, Inc. | $12 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-28 | JAZZ PHARMACEUTICALS INC. | $27 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-08-28 | Regeneron Healthcare Solutions, Inc. | $13 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-27 | Baxter Healthcare | $20 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-08-26 | Novartis Pharmaceuticals Corporation | $30 | Food and Beverage | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-08-25 | Insmed, Inc. | $4 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-24 | Insmed, Inc. | $20 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-22 | HARMONY BIOSCIENCES LLC | $20 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-08-21 | Amgen Inc. | $34 | Education | In-kind items and services | 2025 | ||
| 2025-08-21 | Insmed, Inc. | $16 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-21 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-08-20 | United Therapeutics Corporation | $6 | Food and Beverage | In-kind items and services | Orenitram Drug, Pulmonary Arterial Hypertension | 2025 | |
| 2025-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-18 | Takeda Pharmaceuticals U.S.A., Inc. | $26 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-07 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-08-05 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-04 | Insmed, Inc. | $9 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-07-31 | Actelion Pharmaceuticals US, Inc. | $39 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-07-30 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-07-30 | Regeneron Healthcare Solutions, Inc. | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-28 | HARMONY BIOSCIENCES LLC | $20 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | Axsome Therapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-07-08 | Mallinckrodt Hospital Products Inc. | $21 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-07-07 | Actelion Pharmaceuticals US, Inc. | $15 | Food and Beverage | In-kind items and services | OPSUMIT Drug, Cardiology | 2025 | |
| 2025-07-03 | United Therapeutics Corporation | $12 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-07-02 | GENZYME CORPORATION | $3,425 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-02 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-07-01 | Philips North America LLC | $15 | Food and Beverage | Cash or cash equivalent | Vest Therapy Und Device, Medical Device | 2025 | |
| 2025-06-30 | Regeneron Healthcare Solutions, Inc. | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-25 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-24 | GENZYME CORPORATION | $369 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-06-23 | Avadel CNS Pharmaceuticals, LLC | $21 | Food and Beverage | In-kind items and services | LUMRYZ Drug, CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | 2025 | |
| 2025-06-23 | United Therapeutics Corporation | $8 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-06-22 | AstraZeneca Pharmaceuticals LP | $150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-06-18 | United Therapeutics Corporation | $8 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-06-16 | Axsome Therapeutics, Inc. | $22 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-06-16 | GENZYME CORPORATION | $7 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-16 | GENZYME CORPORATION | $6 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-06-10 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-09 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-06-09 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-05 | JAZZ PHARMACEUTICALS INC. | $23 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-06-04 | Insmed, Inc. | $3 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-06-03 | Actelion Pharmaceuticals US, Inc. | $30 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-05-29 | ARS Pharmaceuticals Operations, Inc. | $28 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-05-29 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-05-28 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-05-28 | Insmed, Inc. | $5 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-05-27 | Avadel CNS Pharmaceuticals, LLC | $21 | Food and Beverage | In-kind items and services | LUMRYZ Drug, CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | 2025 | |
| 2025-05-16 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-05-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2025 | |
| 2025-05-13 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | Itamar Medical Inc | $44 | Food and Beverage (2 payments) | Cash or cash equivalent | WatchPATONE Device, Sleep Apnea testing | 2025 | |
| 2025-05-08 | GlaxoSmithKline, LLC. | $24 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-05-06 | Actelion Pharmaceuticals US, Inc. | $38 | Food and Beverage | In-kind items and services | UPTRAVI Drug, Cardiology | 2025 | |
| 2025-05-06 | ZOLL Respicardia, Inc. | $35 | Food and Beverage | Cash or cash equivalent | remede System Device, Respiratory | 2025 | |
| 2025-05-06 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-06 | Baxter Healthcare | $13 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-05-06 | GENZYME CORPORATION | $10 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-01 | Viatris Specialty LLC | $16 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-05-01 | Currax Pharmaceuticals LLC | $15 | Food and Beverage | In-kind items and services | CONTRAVE Drug, Obesity | 2025 | |
| 2025-05-01 | JAZZ PHARMACEUTICALS INC. | $10 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-04-29 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | ZEPBOUND Drug, Obesity | 2025 | |
| 2025-04-28 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-04-16 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-04-16 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-04-15 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-04-08 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-04-08 | JAZZ PHARMACEUTICALS INC. | $10 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-04-07 | United Therapeutics Corporation | $9 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-03-31 | Viatris Specialty LLC | $23 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-03-27 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-27 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-03-26 | Regeneron Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-03-25 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-03-24 | Grifols USA, LLC | $29 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-03-24 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-03-20 | United Therapeutics Corporation | $9 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-03-18 | JAZZ PHARMACEUTICALS INC. | $9 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-03-18 | JAZZ PHARMACEUTICALS INC. | $4 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-03-16 | JAZZ PHARMACEUTICALS INC. | $28 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-03-15 | GENZYME CORPORATION | $169 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-14 | GENZYME CORPORATION | $7,070 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-11 | Axsome Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-03-10 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-03-06 | GENZYME CORPORATION | $3,978 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-03-06 | GENZYME CORPORATION | $125 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-03-06 | JAZZ PHARMACEUTICALS INC. | $24 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-03-06 | United Therapeutics Corporation | $9 | Food and Beverage | In-kind items and services | Tyvaso Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | 2025 | |
| 2025-03-05 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-03-04 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-03-03 | GENZYME CORPORATION | $9 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-02-20 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-02-11 | Bayer Healthcare Pharmaceuticals Inc. | $21 | Food and Beverage | In-kind items and services | Adempas Drug, Cardio-pulmonary | 2025 | |
| 2025-02-10 | Axsome Therapeutics, Inc. | $24 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-02-10 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-02-07 | AstraZeneca Pharmaceuticals LP | $950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-02-06 | JAZZ PHARMACEUTICALS INC. | $5 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-02-04 | HARMONY BIOSCIENCES LLC | $21 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-02-03 | Avadel CNS Pharmaceuticals, LLC | $15 | Food and Beverage | In-kind items and services | LUMRYZ Drug, CENTRAL NERVOUS SYSTEM CNS NEUROLOGY | 2025 | |
| 2025-02-02 | JAZZ PHARMACEUTICALS INC. | $16 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-01-29 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | XOLAIR Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-01-27 | AstraZeneca Pharmaceuticals LP | $109 | Food and Beverage (13 payments) | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-27 | Merck Sharp & Dohme LLC | $20 | Food and Beverage | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | 2025 | |
| 2025-01-23 | GENZYME CORPORATION | $5,202 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-01-23 | GENZYME CORPORATION | $154 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-23 | GENZYME CORPORATION | $104 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-01-23 | Takeda Pharmaceuticals U.S.A., Inc. | $14 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-01-23 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-23 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-21 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-01-21 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-21 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-19 | JAZZ PHARMACEUTICALS INC. | $30 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-01-16 | JAZZ PHARMACEUTICALS INC. | $11 | Food and Beverage | In-kind items and services | XYWAV Drug, NEUROLOGY | 2025 | |
| 2025-01-13 | AstraZeneca Pharmaceuticals LP | $24 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-01-13 | GlaxoSmithKline, LLC. | $9 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-01-07 | HARMONY BIOSCIENCES LLC | $13 | Food and Beverage | In-kind items and services | WAKIX Drug, NARCOLEPSY | 2025 | |
| 2025-01-07 | United Therapeutics Corporation | $8 | Food and Beverage | In-kind items and services | Orenitram Drug, Pulmonary Arterial Hypertension | 2025 | |
| 2024-12-19 | Mylan Specialty L.P. | $17 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2024 | |
| 2024-12-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6 | Food and Beverage | In-kind items and services | OFEV Drug, RESPIRATORY | 2024 | |
| 2024-12-18 | AstraZeneca Pharmaceuticals LP | $16 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-12-16 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2024 | |
| 2024-12-13 | Electromed, Inc. | $39 | Food and Beverage | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2024 | |
| 2024-12-10 | Takeda Pharmaceuticals U.S.A., Inc. | $28 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2024 | |
| 2024-12-10 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-12-10 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 |
The latest 200 records of 1,578.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $114 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-14 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $977 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-10-30 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $3,000 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-30 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $11,000 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-30 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $1,200 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-23 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $42 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-23 | Regeneron Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $29 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-22 | SANOFI US SERVICES INC. | Premier Pulmonary Critical Care And Sleep Medicine PA | $16,000 | A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and saf | 2025 |
| 2025-10-17 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $9,998 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-10-06 | United Therapeutics Corporation | Premier Pulmonary cc and sleep Medicine | $3,331 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-07-16 | AstraZeneca Pharmaceuticals LP | PREMIER PULMONARY | $301 | A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Sa | 2025 |
| 2025-07-04 | United Therapeutics Corporation | Premier Pulmonary cc and sleep Medicine | $1,500 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-06-23 | AstraZeneca Pharmaceuticals LP | CARDIOVOYAGE LLC | $4,567 | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium | 2025 |
| 2025-06-10 | Cumberland Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE | $12,228 | ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | 2025 |
| 2025-06-10 | Cumberland Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE | $13,350 | ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | 2025 |
| 2025-04-28 | Bayer Healthcare Pharmaceuticals Inc. | Premier Pulmonary Critical Care And Sleep Medicine Admin | $4,590 | BAY 632521, RiOciguAt UseRs Registry The ROAR registry | 2025 |
| 2025-04-28 | Bayer Healthcare Pharmaceuticals Inc. | Premier Pulmonary Critical Care And Sleep Medicine Admin | $2,510 | BAY 632521, RiOciguAt UseRs Registry The ROAR registry | 2025 |
| 2025-03-31 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $870 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-03-31 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-03-19 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-03-19 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-03-19 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-03-17 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $6,888 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-03-17 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-03-17 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $152 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $152 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $40 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,210 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,088 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,251 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,088 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $152 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $42 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $152 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-02-21 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-01-28 | GlaxoSmithKline, LLC. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $7,500 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2025 |
| 2025-01-28 | GlaxoSmithKline, LLC. | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $2,500 | A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GR | 2025 |
| 2025-01-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $9,185 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-01-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-01-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-01-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-01-13 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2025 |
| 2025-01-09 | United Therapeutics Corporation | Premier Pulmonary cc and sleep Medicine | $1,500 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2025 |
| 2025-01-08 | AstraZeneca Pharmaceuticals LP | PREMIER PULMONARY CRITICAL CARE AND SLEEP MEDICINE | $2,711 | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Effi | 2025 |
| 2025-01-03 | Cumberland Pharmaceuticals, Inc. | PREMIER PULMONARY CRITICAL CARE & SLEEP MEDICINE | $7,500 | ORAL IFETROBAN IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) | 2025 |
| 2024-12-25 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-25 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-25 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $152 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,105 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,210 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,330 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,064 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,251 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $152 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-12-16 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $152 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-11-27 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-11-27 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-11-27 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-11-22 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,500 | A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharma | 2024 |
| 2024-11-12 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $7,654 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-09 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $19,135 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-09 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-09 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-09 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-03 | United Therapeutics Corporation | Premier Pulmonary cc and sleep Medicine | $4,981 | PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) | 2024 |
| 2024-10-01 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $3,827 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-01 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-10-01 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $0 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,223 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,251 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,105 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,698 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $209 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $40 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,251 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,223 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,387 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
| 2024-09-30 | Insmed, Inc. | Premier Pulmonary Critical Care And Sleep Medicine PA | $1,105 | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denison, TX, county Grayson County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Denison, TX | County Grayson County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 25,778 | 143,337 | 30,188,424 |
| Population, 2020 census P1 | 24,479 | 135,543 | 29,145,505 |
| Median age B01002 | 40.4 | 39.0 | 35.6 |
| Under 18 B01001 | 25.1% | 24.0% | 25.0% |
| 65 and over B01001 | 20.1% | 18.1% | 13.4% |
| Households B11001 | 10,386 | 55,248 | 10,992,816 |
| Foreign born B05002 | 6.3% | 7.7% | 17.6% |
| Median household income B19013 | $67,365 | $72,182 | $78,476 |
| Median family income B19113 | $82,891 | $88,124 | $94,599 |
| Per capita income B19301 | $34,603 | $38,174 | $40,752 |
| Poverty rate B17001 | 15.0% | 11.2% | 13.8% |
| Unemployment rate B23025 | 4.6% | 3.1% | 5.3% |
| Civilian labor force B23025 | 11,995 | 70,551 | 15,233,563 |
| Mean commute (minutes) B08013 | 19.4 | 25.8 | 26.7 |
| Bachelor's degree or higher B15003 | 18.7% | 23.9% | 33.8% |
| Housing units B25001 | 11,397 | 62,132 | 12,128,515 |
| Owner-occupied B25003 | 58.6% | 66.8% | 62.6% |
| Renters B25003 | 41.4% | 33.2% | 37.4% |
| Median home value B25077 | $180,900 | $248,400 | $283,800 |
| Median gross rent B25064 | $1,309 | $1,310 | $1,403 |
| White, not Hispanic B03002 | 66.5% | 71.1% | 39.1% |
| Black B03002 | 6.8% | 5.1% | 11.9% |
| Hispanic or Latino B03002 | 16.2% | 16.3% | 39.7% |
| Asian B03002 | 1.2% | 1.5% | 5.5% |
| American Indian and Alaska Native B03002 | 0.5% | 0.4% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denison, TX.
Comments